Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02613182 · ClinicalTrials.gov registry record · Phase 2
Open-label Extension Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis
A Phase 2 study, sponsored by Prothena Biosciences.
- Terminated
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
NCT02613182 is a Phase 2 study that was terminated before completion, run by Prothena Biosciences. The registered enrollment target is 34 participants.
The verdict
NCT02613182, a Phase 2 study, was terminated before completion, sponsored by Prothena Biosciences.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
Study Summary
The rationale for this study is to provide additional treatment with NEOD001 for subjects who complete Study NEOD001-001, and to continue to evaluate long term safety and tolerability. All subjects in the current NEOD001 trials are being dosed at 24 mg/kg, which will be continued in this study.
Interventions
- DRUG NEOD001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2016-02 |
| Est. Completion | 2018-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02613182
The ClinicalTrials.gov registry entry for NCT02613182 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Prothena Biosciences, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which NEOD001 is the first listed.
NCT02613182 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02613182 about?
NCT02613182 is a clinical study titled "Open-label Extension Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis". The rationale for this study is to provide additional treatment with NEOD001 for subjects who complete Study NEOD001-001, and to continue to evaluate long term safety and tolerability. All subjects in the current NEOD001 trials are being dosed at 24 mg/kg, which will be continued in this study.
What is the current status of trial NCT02613182?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2016-02. Estimated completion is 2018-05.
What interventions are being tested in trial NCT02613182?
The interventions under investigation include: NEOD001 (DRUG).
Who is sponsoring clinical trial NCT02613182?
This trial is sponsored by Prothena Biosciences, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.